PSYCHEQUALI: Qualitative Study About Psychedelics Using in Psychiatric Disorders

Sponsor

University Hospital, Toulouse (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT06014164

Collaborator

(none)

Enrollment

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

This study is set up to better understand the current use of psychedelics in France in the general population. We focus on individuals who have used any type of psychedelic drug in order to suppress or alleviate a psychiatric symptom in the context of a diagnosed pathology. The data are collected during a semi-structured interview and then studied in a thematic analysis.

Condition or Disease	Intervention/Treatment	Phase
Psychiatric Disorder	Diagnostic Test: Interview

Study Design

Study Type:

Observational

Anticipated Enrollment :

25 participants

Observational Model:

Case-Only

Time Perspective:

Prospective

Official Title:

Qualitative Study of the Self-administered Therapeutic Use of Psychedelics in People With Psychiatric Disorders

Anticipated Study Start Date :

Sep 10, 2023

Anticipated Primary Completion Date :

Mar 10, 2025

Anticipated Study Completion Date :

Mar 10, 2025

Arms and Interventions

Arm	Intervention/Treatment
Patients using psychedelic substances Adult patients self-administering psychedelic substances in psychiatric disorders	Diagnostic Test: Interview An interview will be conducted to describe the experiences of people with psychiatric disorders who use psychedelic substances for therapeutic purposes

Arm

Intervention/Treatment

Patients using psychedelic substances

Adult patients self-administering psychedelic substances in psychiatric disorders

Diagnostic Test: Interview

An interview will be conducted to describe the experiences of people with psychiatric disorders who use psychedelic substances for therapeutic purposes

Outcome Measures

Primary Outcome Measures

Experiences of people using psychedelic substances [Baseline]
The experiences of people with psychiatric disorders who use psychedelic substances for therapeutic purposes will be assessed by interview

Secondary Outcome Measures

Profile of people using psychedelic substances [Baseline]
The profile of people with psychiatric disorders who use psychedelic substances for therapeutic purposes will be assessed by interview

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients diagnosed with a psychiatric disorder by a psychiatrist or general practitioner
Patients used psychedelic or related substances in order to treat psychiatric symptoms
Adults patients (>18 years old)
Patients have given their oral non-opposition
Patients affiliated to a social security scheme

Exclusion Criteria:

Patients who don't speak or understand French
Patients under protection, guardianship or curators

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

University Hospital, Toulouse

Investigators

Principal Investigator: Antoine YRONDI, PH, University Hospital, Toulouse

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

University Hospital, Toulouse

ClinicalTrials.gov Identifier:

NCT06014164

Other Study ID Numbers:

RC31/23/0396
2023-A01575-40

First Posted:

Aug 28, 2023

Last Update Posted:

Aug 28, 2023

Last Verified:

Aug 1, 2023

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Keywords provided by University Hospital, Toulouse

Psychiatric disorder

Psychedelics

Additional relevant MeSH terms:

Mental Disorders

Problem Behavior

Study Results

No Results Posted as of Aug 28, 2023